bluebird bio to Present New Data from LentiGlobinTM Transfusion-Dependent ß-Thalassemia and Severe Sickle Cell Disease Clinical Studies at Annual Congress of the European Hematology Associ...
bluebird bio, Inc. (BLUE)
Last bluebird bio, inc. earnings: 2/18 04:05 pm
Check Earnings Report
US:NASDAQ Investor Relations:
investor.bluebirdbio.com/investor-overview
Company Research
Source: Business Wire
- Oral presentation of updated data from Phase 3 Northstar-2 (HGB-207) study of LentiGlobin in patients with transfusion-dependent ß-thalassemia (TDT) and non-ß0/ß0 genotypes – - Oral presentation of interim data from patients treated with updated study protocol of Phase 1 HGB-206 study of LentiGlobin in patients with severe sickle cell disease (SCD) – - Encore oral presentation of data from CRB-401 study of bb2121 in relapsed/refractory multiple myeloma– - Company to host conference call and live webcast, Friday, June 15, 8:00 a.m. EST – CAMBRIDGE, Mass.--(BUSINESS WIRE)-- bluebird bio, Inc. (Nasdaq: BLUE) announced that data from ongoing LentiGlobin clinical studies in transfusion-dependent ß-thalassemia (TDT) and severe sickle cell disease (SCD) will be highlighted in oral presentations at the 23rd Congress of the European Hematology Association (EHA). An encore
Show less
Read more
Impact Snapshot
Event Time:
BLUE
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
BLUE alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
BLUE alerts
High impacting bluebird bio, Inc. news events
Weekly update
A roundup of the hottest topics
BLUE
News
- May 28, 2024 Deadline: Contact Levi & Korsinsky to Join Class Action Suit Against BLUEAccesswire
- bluebird bio, Inc. Sued for Securities Law Violations - Contact Levi & Korsinsky Before May 28, 2024 to Discuss Your Rights – BLUEAccesswire
- Levi & Korsinsky Announces the Filing of a Securities Class Action on Behalf of bluebird bio, Inc. (BLUE) ShareholdersAccesswire
- Levi & Korsinsky Reminds Shareholders of a Lead Plaintiff Deadline of May 28, 2024 in bluebird bio Lawsuit – BLUEAccesswire
- DEADLINE ACTION ALERT: The Schall Law Firm Encourages Investors in bluebird bio, Inc. with Losses of $100,000 to Contact the FirmAccesswire
BLUE
Earnings
- 11/7/23 - Beat
BLUE
Sec Filings
- 4/16/24 - Form 8-K
- 4/10/24 - Form SC
- 3/26/24 - Form 8-K
- BLUE's page on the SEC website